Literature DB >> 11832341

Hyperglycemia increases endothelial superoxide that impairs smooth muscle cell Na+-K+-ATPase activity.

Sandeep Gupta1, Eugene Chough, Jennifer Daley, Peter Oates, Keith Tornheim, Neil B Ruderman, John F Keaney.   

Abstract

Nitric oxide (NO) plays an important role in the control of numerous vascular functions including basal Na+-K+-ATPase activity in arterial tissue. Hyperglycemia inhibits Na+-K+-ATPase activity in rabbit aorta, in part, through diminished bioactivity of NO. The precise mechanism(s) for such observations, however, are not yet clear. The purpose of this study was to examine the role of superoxide in modulating NO-mediated control of Na+-K+-ATPase in response to hyperglycemia. Rabbit aorta incubated with hyperglycemic glucose concentrations (44 mM) demonstrated a 50% reduction in Na+-K+-ATPase activity that was abrogated by superoxide dismutase. Hyperglycemia also produced a 50% increase in steady-state vascular superoxide measured by lucigenin-enhanced chemiluminescence that was closely associated with reduced Na+-K+-ATPase activity. Specifically, the hyperglycemia-induced increase in vascular superoxide was endothelium dependent, inhibited by L-arginine, and stimulated by N(omega)-nitro-L-arginine. Aldose reductase inhibition with zopolrestat also inhibited the hyperglycemia-induced increase in vascular superoxide. In each manipulation of vascular superoxide, a reciprocal change in Na+-K+-ATPase activity was observed. Finally, a commercially available preparation of Na+-K+-ATPase was inhibited by pyrogallol, a superoxide generator. These data suggest that hyperglycemia induces an increase in endothelial superoxide that inhibits the stimulatory effect of NO on vascular Na+-K+-ATPase activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832341     DOI: 10.1152/ajpcell.00343.2001

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  20 in total

1.  Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells.

Authors:  Viktor R Drel; Pal Pacher; Martin J Stevens; Irina G Obrosova
Journal:  Free Radic Biol Med       Date:  2006-01-31       Impact factor: 7.376

Review 2.  Mechanisms involved in platelet hyperactivation and platelet-endothelium interrelationships in diabetes mellitus.

Authors:  Mariella Trovati; Giovanni Anfossi
Journal:  Curr Diab Rep       Date:  2002-08       Impact factor: 4.810

3.  Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.

Authors:  Irina G Obrosova; Pal Pacher; Csaba Szabó; Zsuzsanna Zsengeller; Hiroko Hirooka; Martin J Stevens; Mark A Yorek
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

4.  Effect of chemical chaperones on glucose-induced lysozyme modifications.

Authors:  S Zahra Bathaie; B B Fateme Nobakht; Hossein Mirmiranpour; Akbar Jafarnejad; S Zahra Moosavi-Nejad
Journal:  Protein J       Date:  2011-10       Impact factor: 2.371

5.  Tamoxifen dilates porcine coronary arteries: roles for nitric oxide and ouabain-sensitive mechanisms.

Authors:  H S Leung; L M Yung; F P Leung; X Yao; Z Y Chen; W H Ko; I Laher; Y Huang
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

Review 6.  Mechanisms for early microvascular injury in obesity and type II diabetes.

Authors:  H Glenn Bohlen
Journal:  Curr Hypertens Rep       Date:  2004-02       Impact factor: 5.369

7.  Urocortin ameliorates diabetic nephropathy in obese db/db mice.

Authors:  X Li; J Hu; R Zhang; X Sun; Q Zhang; X Guan; J Chen; Q Zhu; S Li
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

Review 8.  EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes.

Authors:  Pamela Ouyang; Sheldon H Gottlieb; Valerie L Culotta; Ana Navas-Acien
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931

9.  Metabolic dysfunction in obstructive sleep apnea: A critical examination of underlying mechanisms.

Authors:  Omar A Mesarwi; Ellora V Sharma; Jonathan C Jun; Vsevolod Y Polotsky
Journal:  Sleep Biol Rhythms       Date:  2015-01       Impact factor: 1.186

10.  Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis.

Authors:  Viktor R Drel; Pal Pacher; Tayyeba K Ali; Jeho Shin; Ulrich Julius; Azza B El-Remessy; Irina G Obrosova
Journal:  Int J Mol Med       Date:  2008-06       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.